Leads Biolabs
礼新医药
elsewhere's corpus doesn't contain a real profile of Leads Biolabs (礼新医药) — no coverage of its founding, team, pipeline, or financing history. The one substantive fact available comes via Qiming Venture Partners' own materials: Leads Biolabs is a Chinese biotech that Qiming invested in, and Qiming describes itself as the company's largest shareholder; in a notable transaction, Merck (MSD) acquired Leads Biolabs' PD-1/VEGF bispecific antibody, a deal Qiming partner Kan Chen cited as part of the wave of China innovative-drug out-licensing that followed in the wake of BioNTech's acquisition of Biotheus (普米斯). Beyond that, the company appears only as a name in Qiming's portfolio roundups. For anything more detailed, the article list below is all the corpus currently offers.
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners Donates to Support Rescue and Reconstruction Efforts After Tibet Gyirong Mudslide Disaster
Supporting the Tibet Autonomous Region Charity Federation in disaster relief and post-disaster reconstruction efforts, providing emergency rescue and long-term assistance to affected populations.
Qiming Venture Partners Weekly: Top 10 Portfolio Company Updates Vol. 28, Sep. 2, 2026
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Vol.27, 2026.8.26
Celebrating milestone moments with Qiming Venture Partners' portfolio companies.
Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Companies Vol.26, Aug. 18, 2026
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners and Portfolio Companies Win 2026 Golden Eagle Venture Capital and Sci-Tech Innovation Seedling Awards
Continuously identifying outstanding leaders in the venture capital and startup space, while witnessing entrepreneurial ventures grow from tender "new shoots" into towering trees.
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.25, 2026.8.11
Following Qiming Venture Partners' portfolio companies as they hit milestone moments.
Qiming Star | Immune-Mediated Disease Leader Attovia Therapeutics Debuts on Nasdaq | Bilingual
Focused on developing next-generation biotherapeutics for immune-mediated diseases with significant unmet clinical needs.
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.24, 2026.8.4
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners | WAIC Qiming Venture Partners Entrepreneurship and Investment Forum—The Evolution from Computing Power Origin to Application Success Held in Shanghai
As one of the most forward-looking and influential venture capital firms in artificial intelligence, Qiming Venture Partners has hosted this forum for four consecutive years. It is also the only forum at this year's World Artificial Intelligence Conference initiated by a venture capital firm, designed to showcase and explore the latest breakthroughs in AI's evolution from underlying computing power to industrial application — all through the lens of innovation.
Qiming Weekly | 10 Updates from Qiming Venture Partners Portfolio Vol.23, 2026.7.7
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Qiming Weekly | Top 10 News from Qiming Venture Partners' Portfolio Companies Vol.21, 2026.6.23
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners' William Hu: Healthcare Investment Isn't About Hot or Cold Sectors—It's About Whether There's Enough Disruptive Potential
Someday, as China's economic and innovative strength grows, the value of Chinese entrepreneurs will naturally be reassessed.
Qiming Weekly | Qiming Venture Partners Portfolio News: Top 10 Updates Vol.20, June 16, 2026
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Qiming View | William Hu: Globalization of China's Healthcare Innovation Just Beginning, Will Be Investment Theme for Next 10-20 Years
China's healthcare innovation globalization has only just begun, and it will remain a sustained investment theme for the next 10-20 years.
Qiming Headlines: Intelligence Ignites the Future — Qiming Venture Partners' 17th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
Qiming Venture Partners Maintains Investment Discipline, Proactively Captures Market Opportunities as Deal Flow Continues
Qiming Venture Partners Weekly | Top 10 Portfolio Company Updates Vol.19, June 9, 2026
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Qiming Venture Partners Portfolio Company Tiachen Biologics, a Leader in Allergy and Autoimmune Innovative Drugs in China, Successfully Lists on Hong Kong Exchanges and Clearing Limited
In 2024, Qiming Venture Partners led TianChen Bio's Series B2 round, and then co-led the company's Series C round in 2025.
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Vol.18, 2026.6.2
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners' William Hu: China Is Seeing the Birth of a Wave of Global Pharmaceutical Companies
Over the next five to ten years, more highly original R&D breakthroughs are expected to emerge from labs in China and contribute to global pharmaceutical innovation.
Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Companies Vol.17, 2026.5.26
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners and Nearly 40 Portfolio Companies Named to VBData 2026 Future Healthcare 100
China's most authoritative and influential innovation benchmark for the healthcare industry
Qiming Headlines | Qiming Venture Partners Healthcare Innovation Investment Team Launches 2026 PhD Summer Internship Program | Bilingual
In this 8–10 week internship program, you'll have the opportunity to work alongside some of the most innovative founders in biotech, health tech, and AI-powered healthcare — with dedicated growth opportunities built just for you.
Qiming Venture Partners Weekly | Top 10 Portfolio Company Updates Vol.15, April 28, 2026
Staying with you to mark the milestone moments of Qiming Venture Partners' portfolio companies
Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including Top 4 on ChinaVenture's 2025 China Best VC Firms List
The "ChinaVenture Ranking" has been published for 20 consecutive years, and is known throughout the industry for its professionalism, authority, and rigor. It is regarded as a bellwether for China's equity investment industry and serves as an important reference for capital commitments from many large institutional LPs.
Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Companies Vol.14, 2026.4.21
Staying with you to mark the milestone moments of Qiming Venture Partners' portfolio companies.
Qiming Venture Partners | Connecting World-Class Science with Top Investors: Second Round of Startup Proposals Open for Inaugural S2S China Symposium
We sincerely invite top scientists to visit the S2SChina website and submit proposals, embarking on an accelerated journey from the lab to entrepreneurship.
Qiming Venture Partners-backed precision proteomics leader Alamar Biosciences debuts on Nasdaq
Qiming Venture Partners led Alamar Biosciences' Series A round in 2020, and continued to back the company in its Series B and C rounds.
Qiming Venture Partners Portfolio Companies Dominate 2025 New Economy Top 500 List
This ranking systematically maps the landscape, growth momentum, and evolutionary trajectory of China's new economy enterprises.
OriCell Therapeutics Announces $110 Million Pre-IPO Round, Co-Led by Qiming Venture Partners
Global leader in innovative tumor immunotherapy
Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Companies Vol.12, 2026.4.7
Staying with you to mark the milestone moments of Qiming Venture Partners' portfolio companies.
Qiming Venture Partners Exclusively Leads Medway Medical's Series C Financing
a leading player in China's disposable endoscope market
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.10, 2026.3.24
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners and Its Investors Named to Diyixinsheng's 2025 China Investment Institutions and Individuals Rankings
Designed to unearth a genuine "founder's guide to fundraising, an LP's investment reference."
Qiming View | Qiming Venture Partners' Kan Chen: Innovative Drug Primary Market Recovers, Bullish on Domestic FIC Innovative Drugs
Qiming Venture Partners will continue to stand by exceptional companies with a long-term mindset, helping them navigate cycles and expand globally.
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Vol.09, 2026.3.17
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners and Portfolio Company Female Leaders Win Multiple Awards
The list and its curation aim to celebrate women's contributions and achievements in China's equity investment sector and to the Chinese economy.
Qiming Venture Partners Perspective: Deepening China Healthcare Innovation to Build Global Value Core
Let China's medical innovation achievements benefit the world, and make Chinese innovation a major driving force for global healthcare development.
Qiming Venture Partners Wishes You a Happy Lantern Festival of Harmony, Fulfillment, and Good Fortune
A New Year Dawns; Spring's Tidings Have Arrived
Qiming Weekly: Top 10 Portfolio Company Updates, Vol. 06, Feb. 25, 2026
Staying with you through milestone moments for Qiming Venture Partners' portfolio companies
Qiming Venture Partners | Pusilihua Founder Professor Song Yangzhou Named to TIME100 Health 2026 List of World's Most Influential People in Health
In the official selection rationale released by TIME, the focus was on the extraordinary contributions that Professor Songyang Zhou and his team at Pusillabio have made in the field of tuberculosis detection.
Qiming Venture Partners | Global Top Biotech VCs Gather, First S2S China Symposium Startup Proposal Countdown Begins
Top scientists are invited to visit the S2SChina website and submit proposals, embarking on an accelerated journey from the lab to entrepreneurship.
Qiming Venture Partners Portfolio Company Northmed Technology Debuts on STAR Market
In 2020, Qiming Venture Partners led the Series C round for NorthSea Therapeutics and continued to support the company's growth in its Series D round.
Qiming Venture Partners' Zhang Ao: Six Years with NorthMed, Strong Confidence in China Healthcare Innovation Fundamentals
From Qiming Venture Partners' perspective, an increasing number of Chinese medical innovations are demonstrating internationally leading clinical value, and their global competitiveness is rapidly rising.
Qiming Venture Partners and Six Team Members Honored on LP CLUB 2025 Annual Rankings
Recognizing outstanding organizations and individuals who have forged ahead with remarkable achievements over the past year, setting new benchmarks for industry development.
Qiming Venture Partners and Its Investors Win Multiple Awards on China FOF Research Center 2025 Annual Rankings
This is intended to encourage outstanding institutions and talent in private equity fund-of-funds and the broader fund industry, and to promote the healthy development of equity investment.
Qiming Venture Partners Weekly: Top 10 Portfolio Company Updates Vol. 03, Jan. 27, 2026
Join us in celebrating milestone moments for Qiming Venture Partners' portfolio companies
Seven Qiming Venture Partners Portfolio Companies Named to Cyzone 100 Future Unicorns List
Uncovering the Forces of Business Transformation Over the Next 3–5 Years
Qiming Weekly: 10 Portfolio Company Updates, Vol. 02, Jan. 20, 2026
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Weekly: Top 10 Portfolio Company Updates, Vol. 01, Jan. 14, 2026
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Qiming Venture Partners' Alex Zhou: Zhipu AI's Successful IPO Is a Huge Confidence Boost for China's Long-Term Sectors
Qiming Venture Partners adheres to a "half-step ahead" investment methodology: positioning itself before a major wave coalesces into explicit consensus, yet not so early that it enters purely unconverged scientific exploration. This demands deep industry understanding from the firm and a powerful "radar" network to capture convergence signals.
Qiming View | William Hu: China's Innovation Is Moving From Scattered Breakthroughs to Large-Scale, Comprehensive Advances
Over the next 5–10 years, more highly original R&D breakthroughs are expected to emerge from Chinese labs and contribute to global pharmaceutical innovation.
Qiming Venture Partners Investors Land on ChinaVenture 2025 Investor Rankings
A bellwether for China's equity investment industry and a key reference for major institutional LPs when making allocation decisions.
Qiming Venture Partners and Its Investors Win Seven Awards Including Top 10 Best IPO Investment Institutions of 2025 by IPO Zao Zhi Dao
We hope to highlight investment firms that were bolder in their early-stage bets and backed projects that exerted greater influence on their industries and the market at large.
Qiming Star | Biren Technology, Leading Domestic GPU Company, Successfully Lists on Hong Kong Exchanges and Clearing Limited | Bilingual
Qiming Venture Partners was one of Biren Technology's earliest and most steadfast supporters. When Biren Technology was founded in 2019, Qiming Venture Partners came in as a founding investor, leading the company's first funding round, and has continued to back the company's growth ever since.
Qiming Venture Partners Wins Eight Awards in Zero2IPO's 2025 Rankings, Including Third Place Among China's Top VC Firms
The ranking aims to provide a robust evaluation and reference framework for China's equity investment industry.
Qiming Venture Partners Portfolio Company Insilico Medicine Successfully Lists on Hong Kong Exchanges and Clearing Limited
In 2019, Qiming Venture Partners led Insilico Medicine's Series B financing and continued to back the company through its Series C and D rounds. Prior to the IPO, Qiming Venture Partners held approximately 7% of Insilico Medicine's shares, making it one of the company's most important institutional investors.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 45, 2025
Following the milestones of Qiming Venture Partners' portfolio companies, together with you.
Qiming Venture Partners Earns Five Spots on 2025 Forbes China Midas List
Identify and recognize 100 investors who have delivered strong performance over the past five years.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 44, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 43, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Morning Star | Over 20 Qiming Venture Partners Portfolio Companies Win 30 Awards in Zero2IPO's 2025 VENTURE50
The VENTURE50 rankings are China's bellwether for high-growth enterprise investment.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 42, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Qiming Venture Partners Named One of ChinaVenture's 2025 Most LP-Focused VC Firms in China
The "ChinaVenture Ranking" is regarded as a bellwether for China's equity investment industry and serves as an important basis for capital commitments from many large institutional LPs.
Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Aid Fund for Post-Fire Recovery
Qiming Venture Partners responded swiftly, providing tangible support to disaster-affected residents and fulfilling its corporate social responsibility.
Qiming Venture Partners Named to Yicai CFV Top 10 Equity Investment Firms
Financial value is the synthesis of institutional competitiveness, product innovation, human capital, and risk management within the financial industry and markets. It also serves as the micro-foundation for a nation's overall financial strength and stability.
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 41, 2025
Staying with you through milestone moments for Qiming Venture Partners portfolio companies
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 40, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Aureka Biotechnologies Closes Tens of Millions of Dollars in Series A Funding to Accelerate AI-Powered Antibody Design and Innovative Pipeline R&D
A biotech company focused on generative AI-powered antibody drug development
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 39, 2025
Staying with you to mark milestone moments for Qiming Venture Partners' portfolio companies
Qiming Healthcare Partnering Day 2025 Successfully Held in Shanghai, Fostering Partnerships Between Global Pharma Giants and Chinese Biotech Startups
This marks the fourth consecutive year that Qiming Venture Partners has hosted this event, which to date has facilitated hundreds of one-on-one meetings for over a hundred leading global pharmaceutical and investment companies, laying a solid foundation for expanding the scope and elevating the level of collaboration between enterprises.
Qiming Star | Changsen Pharma Raises Hundreds of Millions of Yuan in Series B+ Funding to Accelerate Clinical Research and Global Expansion of Core Pipeline
Changsen Pharma is dedicated to independently developing first-in-class, best-in-class innovative drugs with global intellectual property rights to address unmet clinical needs.
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 38, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Portfolio Companies Make 2025 Beijing Top 100 Private Enterprise Rankings
The list aims to highlight trends in Beijing's private-sector economy and industrial distribution, identify a cohort of high-quality private enterprises that align with the "high-end, precision, and cutting-edge" economic structure and demonstrate leading, exemplary, and driving effects, and encourage and guide private enterprises in practicing new development concepts to promote high-quality growth.
Qiming Venture Partners Portfolio Companies WeRide and Cornerstone Robotics Named to Wealth China's Best Design List 2025
*Wealth* (Chinese edition) has compiled its annual *Wealth* China Best Design list for four consecutive years. This year's selected projects collectively present a profound dialogue between technology and humanity, highlighting the core value of human designers in the AI era — deep empathy and insight, defining complex problems, and imbuing technology with warmth and meaning.
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 37, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Solemn Statement
Qiming Venture Partners and Eight Portfolio Companies Named to China Innovative Drug Decade Honors List
The list aims to honor outstanding institutions, companies, and major innovations that have delivered exceptional performance over the past decade while playing a significant leading and driving role in the upgrade of China's innovative pharmaceutical industry — establishing benchmarks for the sector's next ten-year journey.
Qiming Venture Partners Selected for China Fund Times Second Annual Private Equity and Venture Capital Yinghua Demonstration Cases
The awards aim to establish industry benchmarks for venture capital and private equity, broaden public awareness of equity investment, and promote the sector's standardized development.
Qiming Venture Partners Weekly | Portfolio Company Updates Vol. 34, 2025
Tracking milestone moments with you for Qiming Venture Partners' portfolio companies
Qiming Venture Partners' William Hu: From 'Chasing Concepts' to 'Evaluating Global Data,' China's Pharma Innovation and Investment Logic Is Being Rebuilt
Qiming Venture Partners will continue to support the development of China's innovative pharmaceutical companies, helping Chinese innovation reach the global stage — in other words, "China Innovation, Global Value."
Qiming Portfolio Company Yanyin Technology Partners with HEC Pharm on Strategic AI Collaboration
The two parties will engage in in-depth collaboration on AI agent R&D, using the AI translation agent project as a starting point to develop solutions covering core scenarios including experimental design and IND filing, as well as AI laboratory automation robotics. Together, they will explore the deep application of AI technology across the full drug discovery and development pipeline, accelerating the globalization strategy of East Sunshine Pharmaceutical.
Qiming Weekly | Qiming Venture Partners Portfolio News & Updates Vol. 33, 2025
Celebrating milestone moments with you at Qiming Venture Partners' portfolio companies
Qiming Venture Partners and Six Portfolio Companies Named to 2025 Investment Institution Soft Power Rankings
By constructing a localized private equity valuation framework, FOFWEEKLY aims to advance industry standardization and ultimately establish industry benchmarks that carry social-value leadership.
Qiming Venture Partners Portfolio Companies Named to Shanghai's 2025 Specialized, Refined, and Innovative SME and Innovative SME Lists (Second Batch)
The two initiatives are designed to enhance the innovation capacity and specialization of small and medium-sized enterprises (SMEs), promote high-quality SME development, and support the advancement of industrial foundations and modernization of industrial chains.
Qiming Venture Partners and Founding Managing Partner Duane Kuang Named to Touzijia 2025 China Fund Partners Annual List
The list aims to recognize investment institutions and individual investors who have demonstrated sustained commitment and achieved outstanding results in the equity investment industry over the past year, collectively bearing witness to the industry's moments of glory.
Qiming Venture Partners Weekly | Portfolio News and Updates Vol. 32, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Qiming Venture Partners and Portfolio Companies Win Multiple Awards at 2029 Healthcare Investment Excellence Awards
The Healthcare Investment Excellence Awards have served as an important barometer for assessing corporate market value and institutional brand influence in the healthcare investment industry. Since their inaugural release in 2017, the awards have recognized investment institutions, investors, and healthcare companies with outstanding performance and distinguished contributions each year.
Qiming Venture Partners and Multiple Portfolio Companies Named to Jazzyear's 2024-2025 China Tech Industry Investment Rankings
The list aims to recognize outstanding investment institutions, investors, and science and technology innovation enterprises that have made significant contributions to the development of China's tech industry.
Qiming Venture Partners Weekly | Portfolio Company Updates Vol. 31, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Headlines | US$200 Million Qishun QFLP Project Launches in Kunshan
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 30, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Portfolio Founders Named to Wealth China 40 Under 40 Business Elite Lists
The 40 Under 40 Business Elite list spotlights China's most influential young leaders of the moment, while the 40 Under 40 Most Promising Business Elite list selects the most promising innovators across industries. These are the young people driving change in Chinese business — and shaping the world.
Rongzi China's Zhu Shan and Qiming Venture Partners' Duane Kuang on AI as the Biggest Paradigm Shift and the Next Generation of Classic Investment Cases
Despite the fierce competition in tech today, many niche segments remain underexplored. The AI space will give rise to ecosystem players on the scale of Xiaomi, creating new opportunities for both industry giants and startups.
Qiming Venture Partners Weekly | Portfolio Companies Funding and Updates Vol. 29, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Qiming Venture Partners Portfolio Companies Shine at 2025 World Artificial Intelligence Conference
As one of the most influential industry events in the global artificial intelligence sector, the 2025 World Artificial Intelligence Conference took "Intelligent Era: Shared Responsibility for Our Planet" as its theme, continuing to serve its important roles as a "technology weathervane, application showcase, industry accelerator, and governance forum" — comprehensively presenting the latest developments in cutting-edge AI technology, industrial trends, and global governance practices.
Qiming Weekly | Qiming Venture Partners Portfolio Companies: Funding and Updates Vol. 28, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Livestream Registration | Today! Join the 2025 WAIC Qiming Venture Partners Entrepreneurship and Investment Forum — Venture Capital Enters a Resonance Cycle of AI Technology and Applications
This sub-forum will showcase and explore the latest breakthroughs in AI technology and applications through an innovation lens. Qiming Venture Partners will bring together top scholars and leading entrepreneurs in the field — from both the startup and investment perspectives — for four keynote speeches and four panel discussions.
Qiming Venture Partners and Four Portfolio Founders Named to Cyzone's 2025 Under-40 Investors and Under-35 Entrepreneur Lists
The Under-40 Investors list seeks out the capital scouts who are active on the front lines of venture capital and steadily riding the crest of the wave; the Under-35 Entrepreneur Pioneers list spotlights and energizes a new generation of young talent, capturing the most vibrant pulse of innovation in our era — serving as a vital barometer for spotting tomorrow's business leaders and innovation trends.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 26, 2025
Join us in spotlighting milestone moments for companies in Qiming Venture Partners' portfolio.
Qiming View | William Hu: China's Innovative Drug Industry Is Experiencing a Collective Breakthrough
Qiming Venture Partners' current investment focus is on driving China's innovation onto the global stage and making it an integral part of the worldwide innovation ecosystem.
Qiming Venture Partners Portfolio Companies Named Beijing Digital Economy Benchmark Enterprises
Benchmark enterprises not only drive core growth but also demonstrate and catalyze the shared development of upstream and downstream partners, advancing high-quality growth in the digital economy.
Qiming Venture Partners Portfolio Companies Shine on 2025 China Globalization Rising Stars 100 List
The ranking focuses on companies that achieved at least $10 million in overseas revenue in 2024, as well as companies that have already generated overseas revenue to date and possess strategic deployment capabilities in the global market.
Qiming Venture Partners' Duane Kuang, William Hu, and Alex Zhou Named to PEDaily's 2025 TOP100 Investors List
The awards have been held for ten consecutive editions, becoming a window into observing industry shifts, with the aim of selecting 100 outstanding investors who have delivered strong investment performance while also driving progress in China's venture capital landscape.
Qiming Weekly | Qiming Venture Partners Portfolio Companies Funding and Updates Vol. 23, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Star | Unisound, Pioneer in China AI Technology Commercialization, Successfully Lists on Hong Kong Stock Exchange | Bilingual
Qiming Venture Partners has stood by Unisound for more than a decade. Its investment in the company dates back to the Series A round in 2013, with continued support through the Series B and D1 rounds.
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 22, 2025
Following Qiming Venture Partners' portfolio companies' milestone moments with you
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 21, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners and Four Portfolio Companies Win 2025 Sci-Tech Innovation Golden Bull Awards
The "Golden Bull Award" is one of the most influential honors in China's capital markets. The Sci-Tech Innovation Golden Bull Award aims to showcase outstanding listed and unlisted companies in strategic emerging industries, while also recognizing the patient capital that diligently supports the rise of new high-tech enterprises.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 20, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners' 16th RMB Fund Annual Meeting and Investor Summit Successfully Held in Shanghai
China's high-quality companies have reached a valuation level that's become genuinely attractive.
Qiming Perspective | Qiming Venture Partners' Kan Chen: China's Innovative Drug Exports Hit Record Highs, Where Is Innovative Drug Investment Heading?
Beyond its homegrown efficiency advantages, China's biotech sector must also seize the opportunities presented by global collaborative clinical development in the years ahead — leveraging strengths across different regions worldwide to maximize biotech value creation.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 11, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners and Four Portfolio Companies Named to PharmCube TOP15 Annual Awards
The awards aim to establish benchmark investment institutions and enterprises with annual bellwether significance for China's pharmaceutical industry.
